← 返回

关于 TIL(肿瘤浸润淋巴细胞)的预后价值——一篇批判性评论

英文原题:On the Prognostic Power of Tumor-Infiltrating Lymphocytes - A Critical Commentary.

查看英文原题

On the Prognostic Power of Tumor-Infiltrating Lymphocytes - A Critical Commentary.

PubMed 2022/05/12(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

TIL(肿瘤浸润淋巴细胞)被广泛用作癌症的预后生物标志物。肿瘤部位调节性T细胞(Tregs)或CD8+ T细胞的频率,或它们的比值,是用于评估预后最常见的标志物。这项工作为不同癌症类型中肿瘤内Tregs与生存之间相反的相关性提供了一种可能的解释。本文呈现并讨论了选择首选标志物所涉及的复杂性,包括变异性的影响。在大多数癌症类型中,淋巴细胞频率比值被提议作为首选标志物。该比值与生存直接相关,与癌症类型无关,并且如果这两种淋巴细胞的频率在肿瘤微环境中相互相关,该比值也比每种淋巴细胞各自的频率变异性更小。然而,如果两种淋巴细胞之一的频率变异性很高,放弃比值而选择频率变异性较小的淋巴细胞将改善与生存的相关性,尤其是当这两种细胞在肿瘤内的频率呈负相关时。通过这种方式选择的最佳预后标志物,很可能也将是检查点抑制剂治疗成功的最佳预测指标。

展开英文摘要原文

Tumor-infiltrating lymphocytes are extensively used as prognostic biomarkers in cancer. Regulatory T cells (Tregs) or CD8+ T cells frequencies in tumor site, or their ratio, are the most common markers used to assess prognosis. This work offers a possible explanation for the opposite correlations between intra-tumoral Tregs and survival, associated with different types of cancer.

The complexity involved with the selection of a preferred marker, including the effect of variability, is presented and discussed. The lymphocytes frequency ratio is proposed as the marker of choice in most types of cancer. The ratio correlates directly with survival, irrespective of cancer type and is also less variable than the frequencies of each of the two lymphocytes, if these frequencies correlate with each other in the tumor microenvironment.

However, if the frequency of one of the two lymphocytes is highly variable, abandoning the ratio in favor of the lymphocyte with less variable frequency will improve correlation with survival, especially when the intra-tumoral frequencies of the two species are inversely correlated. It is plausible, that the best prognostic marker selected this way, will be also be the best predictor of checkpoint inhibitor therapy success.

论文信息

作者
Elkoshi Z
单位
Research and Development Department, Taro Pharmaceutical Industries Ltd, Haifa, Israel.Israel
期刊
Frontiers in immunology2022
原文标识
PubMed 35634289 · DOI 10.3389/fimmu.2022.892543